CP 200 mg/m2 i.v., days 3, 4, 5;

MTX 12 mg intrathecal, day 1
 
Remission induction
 DEX 10 mg/m2 oral, days 6-7, 13-16;

VCR 1 mg i.v., days 7, 14;

IDA 8 mg/m2 i.v. (0.5 h), days 7, 8, 14, 15;

CP 500 mg/m2 i.v.(1 h) day 1;

Ara-C 60 mg/m2 i.v., days 22-25, 29-32
 
Consolidation therapy I, III, V
 MTX 500 mg/m2 i.v. (24 h), days 1, 15;

6-MP 25 mg/m2 oral, days 1-20
 
Consolidation therapy II, IV
 Ara-C 75 mg/m2 i.v. (1 h), days 1-5;

VM26 60 mg/m2 i.v. (1 h), days 1-5
 
Study AAU02
 
Induction therapy (de novo Ph+ ALL)
 Daunorubicin 30 mg/m2 i.v., days 1-3, 15-16;

VCR 2 mg total dose i.v., days 1, 8, 15, 22;

CP 750 mg/m2 i.v., days 1, 8;

Prednisone 60 mg/m2 oral, days 1-7, 15-21;

IDA 9 mg/m2 oral, days 1-28;

MTX 15 mg intrathecal, days 1, 8, 15, 22;

Ara-C 40 mg intrathecal, days 1, 8, 15, 22;

Methylprednisolone 40 mg intrathecal, days 1, 8, 15, 22
 
Consolidation (de novo Ph+ ALL)
 Ara-C 1,000 mg/m2/12 h i.v.(3 h), days 1-4;

Mitoxantrone 10 mg/m2 i.v. days 3-5;

MTX 15 mg intrathecal, day 1;

Methylprednisolone 40 mg intrathecal, day 1
 
Study ADE04
 
Prephase
 DEX 10 mg/m2 oral, days 1-5;

CP 200 mg/m2 i.v., days 3-5;

MTX 15 mg intrathecal, day 1
 
Induction therapy I
 DEX 10 mg/m2 oral, days 1-5;

VCR 2 mg i.v., days 6, 13, 20;

Daunorubicin 45 mg/m2 i.v., days 6-7, 13-14
 
Induction therapy II
 CP 1 g/m2 i.v. (1 h), days 26, 46;

Ara-C 75 mg/m2 i.v. (1 h), days 28-31, 35-38, 42-45;

6-MP 60 mg/m2 oral, days 26-46
 
Consolidation therapy
 DEX 10 mg/m2 oral, days 1-5;

Vindesine 3 mg/m2 i.v., day 1;

MTX 1.5 g/m2 i.v. (24 h), day 1;

Etoposide 250 mg/m2 i.v. (1 h) days 4-5;

Ara-C 2x 2 g/m2 i.v. (3 h, q 12 h), day 5
 
Study AJP01
 
Induction therapy
 CP 1.2 g/m2 i.v. (3 h), day 1;

Daunorubicin 60 mg/m2 i.v. (1 h), days 1-3;

Vincristine 1.3 mg/m2 i.v., days 1, 8, 15, 21;

Prednisolone 60 mg/m2/day oral
 
Consolidation therapy
 Alternating chemotherapy course: high dose chemotherapy with MTX 1 g/m2 i.v. (24 h), day 1, and Ara-C 2 g/m2 i.v. (q 12 h), days 2-3, for 4 cycles
 
Maintenance
 VCR 1.3 g/m2 i.v., day 1;

Prednisolone 60 mg/m2 oral, days 1-5
 
Study AUS01
 
Induction-consolidation therapy
 Hyper-CVAD regimen: CP 300 mg/m2 i.v. (3 h, q 12 h), days 1-3; Vincristine 2 mg i.v., days 4, 11;
Doxorubicine 50 mg/m2 i.v. (24 h), day 4;

DEX 40 mg/day on days 1-4 and 11-14, alternated with MTX 1 g/m2 i.v. (24 h), day 1, Ara-C 1 g/m2 i.v. (2 h, q 12 h), days 2-3 (total of 8 courses)

Maintenance
 VCR 2 mg i.v. monthly for 13 months;
Prednisolone 200 mg oral, 5 days per month for 13 months
All treatment regimens include administration of steroids for CNS prophylaxis.
Ara-C: cytosine arabinoside; CP: cyclophosphamide; DEX: dexamethasone; MTX: methotrexate; 6-MP: 6-mercaptopurine VM26: Teniposide; VCR: vincristine; IDA: idarubicine; i.v.: intravenous
Paediatric p